Skip to main content
SpringerLink
Log in

Clinical Features and Complications of Cystic Fibrosis

  • Chapter
  • First Online:
Handbook of Cystic Fibrosis

Abstract

Cystic fibrosis (CF) is a multisystem disease, and its clinical features reflect the broad impact that loss of cystic fibrosis transmembrane conductance regulator (CFTR) function has on multiple organs (Fig. 3.1). However, pulmonary and gastrointestinal disease account for the vast majority of morbidity and mortality in CF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rabin HR, Butler SM, Wohl ME, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2004;37:400–6.

    Article  PubMed  Google Scholar 

  2. Cohen-Cymberknoh M, Kerem E, Ferkol T, Elizur A. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013;68:1157–62.

    Article  PubMed  Google Scholar 

  3. Mott LS, Park J, Gangell CL, et al. Distribution of early structural lung changes due to cystic fibrosis detected with chest computed tomography. J Pediatr. 2013;163:243–8.

    Article  PubMed  Google Scholar 

  4. Sly PD, Gangell CL, Chen L, et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013;368:1963–70.

    Article  CAS  PubMed  Google Scholar 

  5. Linnane BM, Hall GL, Nolan G, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med. 2008;178:1238–44.

    Article  PubMed  Google Scholar 

  6. McColley SA, Ren CL, Schechter MS, et al. Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis. Pediatr Pulmonol. 2012;47:966–72.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Brody AS, Klein JS, Molina PL, Quan J, Bean JA, Wilmott RW. High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr. 2004;145:32–8.

    Article  PubMed  Google Scholar 

  8. Tepper LA, Caudri D, Utens EM, van der Wiel EC, Quittner AL, Tiddens HA. Tracking CF disease progression with CT and respiratory symptoms in a cohort of children aged 6–19 years. Pediatr Pulmonol. 2014;49:1182–9.

    Article  PubMed  Google Scholar 

  9. Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations. J Pediatr. 2006;148:259–64.

    Article  PubMed  Google Scholar 

  10. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331:637–42.

    Article  CAS  PubMed  Google Scholar 

  11. Bilton D, Canny G, Conway S, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros. 2011;10 Suppl 2:S79–81.

    Article  PubMed  Google Scholar 

  12. Flume PA. Pulmonary complications of cystic fibrosis. Respir Care. 2009;54:618–27.

    Article  PubMed  Google Scholar 

  13. Ng MY, Flight W, Smith E. Pulmonary complications of cystic fibrosis. Clin Radiol. 2014;69:e153–62.

    Article  CAS  PubMed  Google Scholar 

  14. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis – state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis. 2003;37 Suppl 3:S225–64.

    Article  PubMed  Google Scholar 

  15. Knutsen AP, Slavin RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol. 2011;2011:843763.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Balfour-Lynn IM, Elborn JS. “CF asthma”: what is it and what do we do about it? Thorax. 2002;57:742–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ren CL, Konstan MW, Rosenfeld M, et al. Early childhood wheezing is associated with lower lung function in cystic fibrosis. Pediatr Pulmonol. 2014;49:745–50.

    Article  PubMed  Google Scholar 

  18. Robertson JM, Friedman EM, Rubin BK. Nasal and sinus disease in cystic fibrosis. Paediatr Respir Rev. 2008;9:213–9.

    Article  PubMed  Google Scholar 

  19. Eggesbø HB, Søvik S, Dølvik S, Kolmannskog F. CT characterization of inflammatory paranasal sinus disease in cystic fibrosis. Acta Radiol. 2002;43:21–8.

    Article  PubMed  Google Scholar 

  20. Hadfield PJ, Rowe-Jones JM, Mackay IS. A prospective treatment trial of nasal polyps in adults with cystic fibrosis. Rhinology. 2000;38:63–5.

    CAS  PubMed  Google Scholar 

  21. Cimmino M, Nardone M, Cavaliere M, et al. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease. Arch Otolaryngol Head Neck Surg. 2005;131:1097–101.

    Article  PubMed  Google Scholar 

  22. Raynor EM, Butler A, Guill M, Bent 3rd JP. Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis. Arch Otolaryngol Head Neck Surg. 2000;126:581–3.

    Article  CAS  PubMed  Google Scholar 

  23. Brennan S, Gangell C, Wainwright C, Sly PD. Disease surveillance using bronchoalveolar lavage. Paediatr Respir Rev. 2008;9:151–9.

    Article  PubMed  Google Scholar 

  24. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol. 2001;32:356–66.

    Article  CAS  PubMed  Google Scholar 

  25. Cystic Fibrosis Foundation Patient Registry. 2014 annual data report. 2015. https://www.cff.org/Our-Research/CF-Patient-Registry/. Accessed 16 Mar 2016.

  26. Hauser AR, Jain M, Bar-Meir M, McColley SA. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev. 2011;24:29–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr. 2002;140:299–305.

    Article  CAS  PubMed  Google Scholar 

  28. Ren CL, Morgan WJ, Konstan MW, et al. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol. 2007;42:513–8.

    Article  PubMed  Google Scholar 

  29. Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010;303:2386–92.

    Article  CAS  PubMed  Google Scholar 

  30. Sawicki GS, Rasouliyan L, Pasta DJ, et al. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol. 2008;43:1117–23.

    Article  PubMed  Google Scholar 

  31. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010;182:627–32.

    Article  PubMed  Google Scholar 

  32. Lo DK, Hurley MN, Muhlebach MS, Smyth AR. Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev. 2015;(2):CD009650.

    Google Scholar 

  33. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34:91–100.

    Article  PubMed  Google Scholar 

  34. Zemanick ET, Emerson J, Thompson V, et al. Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatr Pulmonol. 2015;50:42–8.

    Article  PubMed  Google Scholar 

  35. Mogayzel Jr PJ, Naureckas ET, Robinson KA, et al. Cystic Fibrosis Foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014;11:1640–50.

    Article  PubMed  Google Scholar 

  36. Courtney JM, Dunbar KE, McDowell A, et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros. 2004;3:93–8.

    Article  CAS  PubMed  Google Scholar 

  37. Egan TM, Detterbeck FC, Mill MR, et al. Long term results of lung transplantation for cystic fibrosis. Eur J Cardiothorac Surg. 2002;22:602–9.

    Article  CAS  PubMed  Google Scholar 

  38. Sexton P, Harrison AC. Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J. 2008;31:1322–33.

    Article  CAS  PubMed  Google Scholar 

  39. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:918–51.

    Article  PubMed  Google Scholar 

  40. Jones AM. Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals? Thorax. 2011;66:558–9.

    Article  PubMed  Google Scholar 

  41. Ziedalski TM, Kao PN, Henig NR, Jacobs SS, Ross SJ. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest. 2006;130:995–1002.

    Article  PubMed  Google Scholar 

  42. Bar-On O, Mussaffi H, Mei-Zahav M, et al. Increasing nontuberculous mycobacteria infection in cystic fibrosis. J Cyst Fibros. 2015;14:53–62.

    Article  PubMed  Google Scholar 

  43. Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016;71 Suppl 1:i1–22.

    Article  PubMed  Google Scholar 

  44. Parkins MD, Floto RA. Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis. J Cyst Fibros. 2015;14:293–304.

    Article  CAS  PubMed  Google Scholar 

  45. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.

    Article  CAS  PubMed  Google Scholar 

  46. Lee MR, Sheng WH, Hung CC, Yu CJ, Lee LN, Hsueh PR. Mycobacterium abscessus complex infections in humans. Emerg Infect Dis. 2015;21:1638–46.

    PubMed  PubMed Central  Google Scholar 

  47. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002;35:246–59.

    Article  PubMed  Google Scholar 

  48. Ledder O, Haller W, Couper RT, Lewindon P, Oliver M. Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations. J Gastroenterol Hepatol. 2014;29:1954–62.

    Article  PubMed  Google Scholar 

  49. Gaskin KJ, Durie PR, Lee L, Hill R, Forstner GG. Colipase and lipase secretion in childhood-onset pancreatic insufficiency. Delineation of patients with steatorrhea secondary to relative colipase deficiency. Gastroenterology. 1984;86:1–7.

    CAS  PubMed  Google Scholar 

  50. Kelly T, Buxbaum J. Gastrointestinal manifestations of cystic fibrosis. Dig Dis Sci. 2015;60:1903–13.

    Article  PubMed  Google Scholar 

  51. Greer RM, Buntain HM, Lewindon PJ, et al. Vitamin A levels in patients with CF are influenced by the inflammatory response. J Cyst Fibros. 2004;3:143–9.

    Article  CAS  PubMed  Google Scholar 

  52. Tangpricha V, Kelly A, Stephenson A, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab. 2012;97:1082–93.

    Article  CAS  PubMed  Google Scholar 

  53. Borowitz D, Gelfond D. Intestinal complications of cystic fibrosis. Curr Opin Pulm Med. 2013;19:676–80.

    Article  CAS  PubMed  Google Scholar 

  54. Colombo C, Ellemunter H, Houwen R, et al. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros. 2011;10 Suppl 2:S24–8.

    Article  PubMed  Google Scholar 

  55. Mousa HM, Woodley FW. Gastroesophageal reflux in cystic fibrosis: current understandings of mechanisms and management. Curr Gastroenterol Rep. 2012;14:226–35.

    Article  PubMed  Google Scholar 

  56. El-Chammas KI, Rumman N, Goh VL, Quintero D, Goday PS. Rectal prolapse and cystic fibrosis. J Pediatr Gastroenterol Nutr. 2015;60:110–2.

    Article  PubMed  Google Scholar 

  57. Kobelska-Dubiel N, Klincewicz B, Cichy W. Liver disease in cystic fibrosis. Prz Gastroenterol. 2014;9:136–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Lewindon PJ, Shepherd RW, Walsh MJ, et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology. 2011;53:193–201.

    Article  CAS  PubMed  Google Scholar 

  59. Ooi CY, Durie PR. Cystic fibrosis from the gastroenterologist’s perspective. Nat Rev Gastroenterol Hepatol. 2016;13:175–85.

    Article  CAS  PubMed  Google Scholar 

  60. Schwarzenberg SJ, Thomas W, Olsen TW, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care. 2007;30:1056–61.

    Article  PubMed  Google Scholar 

  61. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32:1626–31.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33:2697–708.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Stalvey MS, Clines GA. Cystic fibrosis-related bone disease: insights into a growing problem. Curr Opin Endocrinol Diabetes Obes. 2013;20:547–52.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005;90:1888–96.

    Article  CAS  PubMed  Google Scholar 

  65. Popli K, Stewart J. Infertility and its management in men with cystic fibrosis: review of literature and clinical practices in the UK. Hum Fertil (Camb). 2007;10:217–21.

    Article  Google Scholar 

  66. Phillipson G. Cystic fibrosis and reproduction. Reprod Fertil Dev. 1998;10:113–9.

    Article  CAS  PubMed  Google Scholar 

  67. di Sant’Agnese PA. Guest editorial – fertility and the young adult with cystic fibrosis. N Engl J Med. 1968;279:103–5.

    Article  PubMed  Google Scholar 

  68. Holsclaw DS, Perlmutter AD, Jockin H, Shwachman H. Genital abnormalities in male patients with cystic fibrosis. J Urol. 1971;106:568–74.

    CAS  PubMed  Google Scholar 

  69. Kaplan E, Shwachman H, Perlmutter AD, Rule A, Khaw KT, Holsclaw DS. Reproductive failure in males with cystic fibrosis. N Engl J Med. 1968;279:65–9.

    Article  CAS  PubMed  Google Scholar 

  70. Pinquart M, Shen Y. Depressive symptoms in children and adolescents with chronic physical illness: an updated meta-analysis. J Pediatr Psychol. 2011;36:375–84.

    Article  PubMed  Google Scholar 

  71. Quittner AL, Abbott J, Georgiopoulos AM. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax. 2016;71:26–34.

    Article  PubMed  Google Scholar 

  72. Di Sant’Agnese PA, Darling RC, Perera GA, Shea E. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas; clinical significance and relationship to the disease. Pediatrics. 1953;12:549–63.

    Google Scholar 

  73. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959;23:545–9.

    CAS  PubMed  Google Scholar 

  74. Moss RB. Drug allergy in cystic fibrosis. In: Moss RB, editor. Cystic fibrosis: infection, immunopathology, and host response. Totowa: Humana Press; 1990. p. 211–29.

    Chapter  Google Scholar 

  75. Parmar JS, Nasser S. Antibiotic allergy in cystic fibrosis. Thorax. 2005;60:517–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Burrows JA, Nissen LM, Kirkpatrick CM, Bell SC. Beta-lactam allergy in adults with cystic fibrosis. J Cyst Fibros. 2007;6:297–303.

    Article  CAS  PubMed  Google Scholar 

  77. Ramesh S. Antibiotic hypersensitivity in patients with CF. Clin Rev Allergy Immunol. 2002;23:123–41.

    Article  CAS  PubMed  Google Scholar 

  78. Thornton J, Rangaraj S. Anti-inflammatory drugs and analgesics for managing symptoms in people with cystic fibrosis-related arthritis. Cochrane Database Syst Rev. 2016;(1):CD006838.

    Google Scholar 

  79. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125(1 Suppl):1S–39.

    Article  PubMed  Google Scholar 

  80. Turner MA, Baildam E, Patel L, David TJ. Joint disorders in cystic fibrosis. J R Soc Med. 1997;90 Suppl 31:13–20.

    PubMed  PubMed Central  Google Scholar 

  81. Bernstein ML, McCusker MM, Grant-Kels JM. Cutaneous manifestations of cystic fibrosis. Pediatr Dermatol. 2008;25:150–7.

    Article  PubMed  Google Scholar 

  82. Darmstadt GL, Schmidt CP, Wechsler DS, Tunnessen WW, Rosenstein BJ. Dermatitis as a presenting sign of cystic fibrosis. Arch Dermatol. 1992;128:1358–64.

    Article  CAS  PubMed  Google Scholar 

  83. Patrizi A, Bianchi F, Neri I, Specchia F. Acrodermatitis enteropathica-like eruption: a sign of malabsorption in cystic fibrosis. Pediatr Dermatol. 2003;20:187–8.

    Article  CAS  PubMed  Google Scholar 

  84. Katz KA, Yan AC, Turner ML. Aquagenic wrinkling of the palms in patients with cystic fibrosis homozygous for the delta F508 CFTR mutation. Arch Dermatol. 2005;141:621–4.

    PubMed  Google Scholar 

  85. Gibney EM, Goldfarb DS. The association of nephrolithiasis with cystic fibrosis. Am J Kidney Dis. 2003;42:1–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, C.S. Mott Children’s Hospital University of Michigan, Ann Arbor, MI, USA

    Amy G. Filbrun

  2. Department of Pediatrics, The University of Vermont College of Medicine, Burlington, VT, USA

    Thomas Lahiri

  3. Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, USA

    Clement L. Ren

Authors
  1. Amy G. Filbrun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Lahiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clement L. Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Filbrun, A.G., Lahiri, T., Ren, C.L. (2016). Clinical Features and Complications of Cystic Fibrosis. In: Handbook of Cystic Fibrosis. Adis, Cham. https://doi.org/10.1007/978-3-319-32504-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32504-0_3

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-32502-6

  • Online ISBN: 978-3-319-32504-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation